Safety Tolerability footer references

September 7, 2012

References 1. Data on File, 309560. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 2. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with
fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer [published errata
appears in

J Clin Oncol.


J Clin Oncol

. 2010;28(30):4594-4600. 3. FASLODEX [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.